Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials

Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials

Abstract Introduction Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the USA and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. In POETYK PSO-1 and PSO-2, deucravacitinib was super...

Full description

Saved in:
Bibliographic Details
Main Authors: April W. Armstrong, Leon Kircik, Linda Stein Gold, Bruce Strober, Claudia H. M. C. De Oliveira, John Vaile, Ying-Ming Jou, Carolin Daamen, Thomas Scharnitz, Mark Lebwohl
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-03-01
Series:Dermatology and Therapy
Subjects:
Alanine aminotransferase
Aspartate aminotransferase
Creatine phosphokinase
Deucravacitinib
Liver function tests
Oral small molecule
Online Access:https://doi.org/10.1007/s13555-025-01362-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01362-w

Similar Items